HSRLCE Self-Study Report
Period: 2017-2022

APPENDICES

MICHAEL J. SOLE ANNUAL CARDIOVASCULAR SCIENTIFIC DAY (ACvSD)

HSRLCE typically hosts the ACvSD every April/May (on non-COVID years); averaging around 220 delegates. Local, national and international experts share their knowledge with the Centre's trainees, faculty, industry, and other healthcare professionals. The Day also sees us host a trainee poster competition with three prizes (worth $1,000, $500 and $250) given to the top three students. We also have a lecture given by the Dr. Subhash C. Verma Young Investigator's Award recipient. The award recognizes exceptional achievement in the cardiovascular sciences and is open to HSRLCE members who have not been principal investigators for more than seven years.

2017 – April 6

Theme: Innovation in Devices, Research and Novel Partnerships

Sessions:

- Innovation in Cardiovascular Devices
- Innovation in Research
- Novel Partnerships
- Trainee Poster Competition

**See flyer for more information*

2018 – April 11

Theme: From Discovery to Clinical Trials

Sessions:

- Valvular Heart Failure
- The PCSK9 Inhibitor Story
- Dragon's Den for Cardiovascular Medicine - Basic Science Stream
- Dragon's Den for Cardiovascular Medicine - Clinical Stream

**See flyer for more information*

2019 – May 3

Theme: Heart Failure

Held in conjunction with the Ted Rogers Centre Heart Failure Symposium

Sessions:

- Basic Science: Uncovering the Future
- Advances Toward Precision Medicine
- Translation: Lab to Clinic
- Innovation
- Prevention & Health Promotion
- Trainee Poster Showcase
- What to Know About Diabetes, Renal Disease and Heart Failure
- Heart Failure: What You Need to Know Right Now
- Emerging Areas, Special Considerations in Heart Failure

**See flyer for more information*

HEART & STROKE / RICHARD LEWAR CENTRE OF EXCELLENCE
Michael J. Sole Annual Cardiovascular Scientific Day
Thursday, April 6, 2017; 7:30am- 5:30 pm

Toronto Reference Library, Bram & Bluma Appel Salon
789 Yonge Street, Toronto, ON M4W 2G8

Innovation in Devices, Research and Novel Partnerships

7:30 - 8:15 am	*Registration, continental breakfast, poster set-up*
8:15 - 8:40 am	**Dr. Michael Farkouh**, HSRLCE Director; and **Dr. Richard Hegele**, Vice Dean, Research and Innovation, Faculty of Medicine, University of Toronto

Innovation in Cardiovascular Devices

8:40 - 8:45 am	*Chair: Dr. Bradley Strauss*
8:45 - 9:05 am	**Dr. Bobby Yanagawa**, Assistant Professor, Division of Cardiac Surgery, St Michael's Hospital, University of Toronto ***"Left Atrial Appendage Closure Devices"***
9:05 - 9:25 am	**Dr. Joseph Cafazzo**, Lead, Centre for Global eHealth Innovation, University Health Network; and Associate Professor, University of Toronto ***"Patient Heal Thyself: The Next Generation of Mobile Health Apps for Self-Care"***
9:25 - 9:45 am	**Dr. Steffen-Sebastian Bolz**, Professor, Department of Physiology, University of Toronto; Principal Investigator at the University of Toronto Translational Biology and Engineering Program (TBEP); and Director of the Toronto Centre for Microvascular Medicine ***"New Concepts in Microvascular Control: Capitalizing on the Vascular Bed-Specific Functions of the Cystic Fibrosis Transmembrane Conductance Regulator and Tumor Necrosis Factor"***
9:45 - 10:05 am	**Session Overview and Active Discussion**
10:05 - 10:20 am	***REFRESHMENT BREAK***

Innovation in Research

10:20 - 10:25 am	*Chair: Dr. Richard Hegele*
10:25 - 11:05 am	***Richard Lewar Lecture:*** **Dr. Calum MacRae**, Chief, Cardiovascular Medicine Division, Brigham and Women's Hospital; and Associate Professor of Medicine, Harvard Medical School ***"Do We Need to Redefine Disease for a Digital Age?"***

11:05 - 11:10 am	*Speaker Introductions*
11:10 - 11:30 am	**Dr. Catherine Coolens**, Assistant Professor, Department of Radiation Oncology and IBBME, University of Toronto; Staff Medical Physicist, Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network; and TECHNA Institute, University Health Network ***"Early Measures of Perfusion and Diffusion Imaging for Treatment Response Assessment"***
11:30 - 11:50 am	**Dr. Erik Yeo**, Professor of Medicine, University of Toronto; and Head of Homostasis and Thrombosis, University Health Network ***"Cancer and Thrombosis"***
11:50 am - 12:00 pm	**Session Overview and Active Discussion**
12:00 - 1:30 pm	***LUNCH AND POSTER SESSION JUDGING***

Novel Partnerships

1:30 - 1:35 pm	*Chairs: Dr. Michael Farkouh and Dr. John Floras*
1:35 - 2:30 pm	**Partnerships with Federal Agencies** o **Dr. Ryan Perry**, Assistant Scientific Director for the Canadian Institutes for Health Research (CIHR) – Institute for Circulatory and Respiratory Health (ICRH) - ***Canadian Institutes of Health Research (CIHR)*** o **Dr. Yves Rosenberg**, Chief, Atherothrombosis and Coronary Artery Disease Branch, Division of Cardiovascular Sciences, National Heart, Lung and Blood Institute - ***National Institutes of Health (NIH)***
2:30 - 3:25 pm	**Partnerships in Clinical Trials** ***"Trial to Assess Chelation Therapy 2 (TACT2)"*** o **Dr. Gervasio Lamas**, Chair of Medicine at Mount Sinai Medical Center; Chief of Cardiology, Columbia University Division of Cardiology at Mount Sinai; and Professor of Medicine, Columbia University Medical Center o **Dr. Jonathan Newman**, Eugene Braunwald M.D. Assistant Professor of Medicine (Cardiology) in the The Leon H. Charney Division of Cardiology and The Center for the Prevention of Cardiovascular Disease at the New York University School of Medicine
3:25 - 3:40 pm	***REFRESHMENT BREAK***
3:40 - 4:10 pm	**Partnerships with International Academic Institutions (Panel Discussion)** o ***Brigham and Women's Hospital*** – **Dr. Calum MacRae** o ***Mount Sinal Medical Centre, Miami*** – **Dr. Gervasio Lamas** o ***New York University*** – **Dr. Jonathan Newman**
4:10 - 4:40 pm	**Partnerships with Industry** **Dr. Alex Romanovschi**, Scientific Director, AstraZeneca Canada "***Pushing the Boundaries of Science"***
4:40 - 4:50 pm	***BREAK***
4:50 - 5:30 pm	***PRESENTATION OF STUDENT POSTER AWARDS***

HEART & STROKE / RICHARD LEWAR CENTRE OF EXCELLENCE
Annual Cardiovascular Scientific Day
Wednesday, April 11, 2018
8:00am- 5:00 pm

Hart House
7 Hart House Cir, Toronto, ON M5S 3H3

FROM DISCOVERY TO CLINICAL TRIALS

8:00 am – 8:15 am	**Registration, continental breakfast, poster set-up**
8:15 am – 8:30 am	**Welcome and Opening Remarks** **Dr. Michael Farkouh**, HSRLCE Director; and **Dr. Richard Hegele**, Vice Dean, Research and Innovation, Faculty of Medicine, University of Toronto

Valvular Heart Disease

8:30am – 8:35 am	*Chairs: Drs. Dennis Ko & Maral Ouzounian*
8:35 am – 9:55 am	**Dr. Craig Simmons,** University of Toronto *Valvular Heart Disease from a Basic/Translational Scientist Perspective* **Dr. Jagdish Butany,** University of Toronto *Valvular Heart Disease from a Pathologist Perspective* **Heart & Stroke Lecture**: **Dr. Josep Rodés-Cabau,** Laval University *Valvular Heart Disease from a Clinician-Scientist Perspective* **Dr. Harindra Wijeysundera,** University of Toronto *Valvular Heart Disease from a Health Services Research Perspective*
9:55 am – 10:25 am	Panel Discussion and Q&A
10:25 am – 10:40 am	**REFRESHMENT BREAK, POSTER VIEWING & DISCUSSION**

Breakout Session I:
Dragon's Den for Cardiovascular Medicine - Basic Science Stream

10:40 am – 10:45 am	*Chairs: Drs. Myron Cybulsky & Kim Connelly*
10:45 am – 12:15 pm	This session will take on a dragon's den format where a panel will listen to proposals* from trainees and faculty and offer their feedback. Panelists will include Drs. Nabil Seidah and Craig Simmons. Senior faculty will also share their career perspective and experiences with mentoring of students. **If you would like to pitch a proposal please send an email to Liz Thuo at hsrl.centre@utoronto.ca*

Breakout Session II:
Dragon's Den for Cardiovascular Medicine - Clinical Stream

10:40 am – 10:45 am	*Chairs: Drs. Brad Strauss & Peter Juni*
10:45 am – 12:15 pm	This session will take on a dragon's den format where a panel will listen to proposals* from trainees and faculty and offer their feedback. Panelists will include Drs. Gary Gershony and Josep Rodés-Cabau. Senior faculty will also share their career perspective and experiences with mentoring of students. This session will also feature a guest speaker: **Dr. Gary Gershony,** John Muir Health Cardiovascular Institute, who will speak on *My Career in Innovation in Cardiovascular Research* **If you would like to pitch a proposal please send an email to Liz Thuo at hsrl.centre@utoronto.ca*
12:15 pm – 1:45 pm	**LUNCH AND POSTER SESSIONS**

The PCSK9 Inhibitor Story

1:45 pm – 1:50 pm	*Chairs: Drs. Beth Abramson & Shaun Goodman*
1:50 pm – 2:15 pm	**Richard Lewar Lecture**: **Dr. Nabil Seidah,** Montreal Clinical Research Institute *The Development of the PCSK9 Story from a Basic Scientist Perspective*
2:15 pm – 2:40 pm	**Dr. Lawrence Leiter,** University of Toronto *The Development of the PCSK9 Story from a Clinician-Scientist Perspective*
2:40 pm – 3:10 pm	Panel Discussion and Q&A
3:10 pm – 3:30 pm	**REFRESHMENT BREAK**
3:30 pm – 4:15 pm	**Dr. Subhash C. Verma Award Lecture** Active Learning: Question and Answer
4:15 pm – 4:45 pm	**Presentation of Student Poster Awards**

HSRLCE MICHAEL J. SOLE ANNUAL CARDIOVASCULAR SCIENTIFIC DAY

in conjunction with

Ted Rogers Centre Heart Failure Symposium

May 3-4, 2019
Marriott Downtown at CF Toronto Eaton Centre (525 Bay Street, Toronto)

FRIDAY, MAY 3, 2019

Time	Session I: Basic Science: Uncovering the Future	
7:30 AM	Breakfast and Registration	
8:30	Welcome and Introduction	**Dr. Mansoor Husain**, Executive Director, Ted Rogers Centre for Heart Research **Dr. Michael Farkouh**, Director, Heart & Stroke/Richard Lewar Centre of Excellence in Cardiovascular Research (HSRLCE)
8:35	How to Maintain the Quality of Heart Cells During Heart Failure: Removal of Cellular Waste and Malfunctioning Organelles by Autophagy	**Dr. Junichi Sadoshima**, Chair, Department of Cell Biology and Molecular Medicine, Rutgers University
8:52	MicroRNAs as Biomarkers and Effectors of Vascular Dysfunction in Heart Failure	**Dr. Jason Fish**, Senior Scientist, Toronto General Hospital Research Institute
9:09	Molecular Imaging of Fibrosis	**Dr. Peter Caravan**, Head, Translational Molecular Imaging Lab and Director, Institute for Innovation in Imaging, Massachusetts General Hospital
9:26	Q&A Session	Full panel
9:46	Flash Science Presentations I	
9:53	Break	
	Session II: Advances Toward Precision Medicine	
10:13	Genetics of Hypertrophic Cardiomyopathy: From Molecules to Medicines	**Dr. Christine Seidman**, Director, Cardiovascular Genetics Center at Brigham and Women's Hospital
10:30	Using AI Methods to Analyze Cardiovascular Surgical Outcomes	**Dr. Edward Hickey**, Cardiovascular Surgeon, The Hospital for Sick Children
10:47	Focus on Precision Phenotyping Using Molecular and Systems Epidemiology	**Dr. Patrick Lawler**, Clinician-Scientist, Peter Munk Cardiac Centre
11:04	Q&A Session	Full panel
11:24	Flash Science Presentations II	
11:31	Lunch Served	
	Lunch Session: Translation: Lab to Clinic	

12:00 PM	From Patient Disease to Therapeutic Discovery: Finding Molecules that Matter	**Dr. Jason Maynes**, Scientist, Molecular Medicine, The Hospital for Sick Children
12:17	Leveraging a Biobank: From Discovery to Diagnostics	**Dr. Phyllis Billia**, Clinician-Scientist, Peter Munk Cardiac Centre
12:34	Paradigm Shift in the Use of Biomaterials for Cardiac Repair: Designing for Immunity Considerations	**Dr. Paul Santerre**, Principal Investigator, Ted Rogers Centre for Heart Research
12:51	Q&A Session	Full panel
1:11	Flash Science Presentations III	
1:18	Break	
	Session IV: Innovation	
1:33	Introduction by Chairs and Overview of Michael R. Freeman Innovation Award Competition	**Dr. Bradley Strauss**, Chief, Schulich Heart Centre, Sunnybrook Health Sciences Centre **Dr. Maral Ouzounian**, Surgeon-Scientist, Peter Munk Cardiac Centre
1:43	Development of a Multiparametric MRI Protocol Assessing Vascular and Metabolic Responses to Exercise in Pediatric Respiratory Disease	**Ms. Jessica Caterini**, CSCP Bigelow Winner, PhD Candidate, Department of Exercise Sciences, University of Toronto
1:50	*Richard Lewar Lecture:* Strengthening the Framework for Canadian Medical Technology Innovations through Education and Commercialization	**Dr. Brian Courtney**, Scientist, Sunnybrook Health Sciences Centre
2:10	Q&A Session	Full panel
	Session V: Prevention & Health Promotion	
2:20	Introduction by Chairs	**Dr. Michael Farkouh,** Director, HSRLCE **Dr. Phyllis Billia**, Clinician-Scientist, PMCC
2:25	Connecting Heart, Brain and Mind: The Time is Now!	**Dr. Sandra Black**, Professor of Medicine (Neurology), University of Toronto & Sunnybrook Health Sciences Centre
2:45	*Great Minds and Great Medicine: the Raymond and Beverly Sackler Visiting Lecture* The Very High-Risk CHD patient: When is More Intensive Cholesterol-Lowering Therapy Warranted?	**Dr. Robert Rosenson**, Professor of Medicine (Cardiology), Mount Sinai Icahn School of Medicine; Director, Cardiometabolic Unit, Mount Sinai Hospital
3:05	*Heart & Stroke Lecture* The Environment and Cardiometabolic Disease: A New Frontier for Sustainable Global Health	**Dr. Sanjay Rajagopalan,** Chief of Cardiovascular Medicine, University Hospitals; Professor, Case Western Reserve School of Medicine
3:25	Q&A Session	Full panel
3:40 – 5:30	**Trainee Showcase and Reception**	

Heart & Stroke | Richard Lewar Centre of Excellence in Cardiovascular Research

TED ROGERS CENTRE FOR HEART RESEARCH

SATURDAY, MAY 4, 2019

Time	Breakfast Session: What to Know About Diabetes, Renal Disease and Heart Failure	
7:50 AM	Welcome and Introduction	**Dr. Mansoor Husain**, Executive Director, Ted Rogers Centre for Heart Research
7:53	What is Heart Failure and how Common is it?	**Dr. Michael McDonald**, Cardiologist, Peter Munk Cardiac Centre
8:10	Type 2 Diabetes and Kidney Dysfunction: how to Prevent Heart Failure	**Dr. Kim Connelly**, Clinician-Scientist, St. Michael's Hospital
8:27	How to Manage Diabetic and Renal Patients with CVD	**Dr. David Cherney**, Clinician-Scientist, University Health Network
8:44	Q&A Session	Full panel
9:00	Break	
	Session II: Heart Failure: What You Need to Know Right Now	
9:20	Heart Failure Care: from the Emergency Room to the Doctor's Office	**Dr. Douglas Lee**, Ted Rogers Chair in Heart Function, Peter Munk Cardiac Centre **Dr. Clare Atzema**, Emergency Physician-Scientist, Sunnybrook Health Sciences Centre
9:35	Translating a Cardiology Consult	**Dr. Jeremy Kobulnik**, Cardiologist, Mount Sinai Hospital
9:50	Is there an ECHO in here? Imaging in HF	**Dr. Gillian Nesbitt**, Cardiologist, Mount Sinai Hospital
10:15	Managing Late-Stage Patients with HFrEF and HFpEF	**Dr. Stephanie Poon**, Cardiologist, Sunnybrook Health Sciences Centre
10:30	Q&A Session	Full panel
10:55	Break	
	Session III: Emerging Areas, Special Considerations in Heart Failure	
11:15	Innovative Therapies on the Horizon	**Dr. Phyllis Billia**, Clinician-Scientist, Peter Munk Cardiac Centre
11:30	Caring for Families with a Heart Failure Diagnosis	**Dr. Aamir Jeewa**, Section Head, Cardiomyopathy & Heart Function Program, The Hospital for Sick Children
11:45	Genetic Testing and the Prevention of Heart Failure	**Dr. Melanie Care**, Genetic Counsellor, University Health Network
Noon	Cardiotoxicity: Protecting the Hearts of Cancer Patients	**Dr. Husam Abdel-Qadir**, Clinician-Scientist, Women's College Hospital
12:15 PM	Q&A Session	Full panel
12:40	End of Program	

CASE-BASED CONTINUING MEDICAL EDUCATIONAL PROGRAMS

HSRLCE held accredited multi-provincial case-based educational programs that offer practical tips that can be used in daily practice. These programs aim to help physicians and specialists increase confidence with the initiation and use of specific cardioprotective therapies.

2018/2019

Diabetes and Cardiovascular Disease: A Practical Guide for Specialists Managing Patients With or At Risk for Cardiovascular Disease

11 sessions in 9 cities across Canada

Learning Objectives

1. Outline the impact of T2DM upon CV morbidity and mortality
2. Describe the role that approved anti-hyperglycemic therapies play in reducing CV risk
3. Select appropriate anti-hyperglycemic agents in order to reduce CV risk in patients with T2DM
4. Develop an integrated management plan in order to meet patient needs and reduce T2DM morbidity and mortality

Scientific Planning Committee Composition:

2 Endocrinologists and 5 Cardiologists from University of Toronto, University of British Columbia and McGill University

2021 – March, April & May

BE IT RESOLVED THAT… An educational debate on optimal cardiorenal protection of patients with or without diabetes

6 sessions cross-Canada (virtual)

Debate Topics

- Be it resolved that the first agent initiated in all patients with type 2 diabetes should be an SGLT2i/GLP1-RA in place of metformin.Innovation in Research
- Be it resolved that in patients with HF (with or without T2DM) an SGLT2i should be prioritized over an ARNi.
- Be it resolved that a GLP1-RA should be prioritized over a SGLT2i for people with T2DM and ASCVD.
- Be it resolved that in patients with albuminuria, and low-normal blood pressure (with or without T2DM), initiating an SGLT2i over an ACE/ARB will provide more nephroprotection.

Learning Objectives

- Discuss the cardiorenal protective role of sodiumglucose transport protein 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1-RA) in patients with and without diabetes.
- Compare different treatment sequencing options for SGLT2i and GLP1-RA in type 2 diabetes mellitus (T2DM), as well as in chronic kidney disease and heart failure populations with or without type 2 diabetes, based on recently published data.

Scientific Planning Committee Composition:

1 Endocrinologist, 1 Cardiologist, 1 Nephrologist and 1 Internist from University of Toronto, University of British Columbia and University of Calgary

2019 (Nov)

Diabetes Connect: A Practicum for Primary Care

1 Session in Toronto

Learning Objectives

- Discuss the interplay between diabetes, cardiovascular and renal disease
- Investigate and manage cardiovascular and renal issues in patients with diabetes
- Apply evidence and guidelines recommendations to reduce cardiovascular and renal risk for patients with diabetes

Scientific Planning Committee Composition:

3 Endocrinologists, 1 Cardiologist, 1 Nephrologist and 1 Clinical Dietician from University of Toronto, and McMaster University

2020/ 2021 – Nov. 2021 – Current (ongoing)

Straight from the Heart – Insights on Optimal Cardioprotection

13+ virtual and in-person sessions cross-Canada

Program Overview

SGLT2is and GLP1-RAs have proven to be effective in reducing cardiovascular risk and improving cardiometabolic health in several patient populations that are seen by cardiologists including ASCVD and HF with or without diabetes. This case-based program offers practical tips and tricks that can be used in daily practice and will help increase confidence with the initiation and use of the cardioprotective therapies.

Learning Objectives

- Recognize the importance of early initiation of cardioprotective therapies (SGLT2 inhibitors) in patients with heart failure with reduced ejection fraction (with or without diabetes)
- Recognize the importance of early initiation of cardioprotective therapies (SGLT2 inhibitors and GLP-1 receptor agonists) in patients with atherosclerotic cardiovascular disease and diabetes
- Initiate SGLT2 inhibitors and GLP-1 receptor agonists in appropriate patients using guideline-recommended strategies
- Advise patients on the safe use of SGLT2 inhibitors and GLP-1 receptor agonists

Scientific Planning Committee Composition:

1 Endocrinologist and 4 Cardiologists from University of Toronto, McGill University, and Université de Sherbrooke

2021 (Feb)

The Heart, the Kidney and SGLT2 Inhibitors: From Clinical Trials to Patient Care

1 Session (virtual)

Program Overview

SGLT2is and GLP1-RAs have proven to be effective in reducing cardiovascular risk and improving cardiometabolic health in several patient populations that are seen by cardiologists including ASCVD and HF with or without diabetes. This case-based program offers practical tips and tricks that can be used in daily practice and will help increase confidence with the initiation and use of the cardioprotective therapies.

Learning Objectives

- Recognize the importance of early initiation of cardioprotective therapies (SGLT2 inhibitors) in patients with heart failure with reduced ejection fraction (with or without diabetes)
- Recognize the importance of early initiation of cardioprotective therapies (SGLT2 inhibitors and GLP-1 receptor agonists) in patients with atherosclerotic cardiovascular disease and diabetes
- Initiate SGLT2 inhibitors and GLP-1 receptor agonists in appropriate patients using guideline-recommended strategies
- Advise patients on the safe use of SGLT2 inhibitors and GLP-1 receptor agonists

Scientific Planning Committee Composition:

1 Endocrinologist, 1 Cardiologist, and 1 Nephrologist from University of Toronto

UNIVERSITY OF TORONTO

Heart & Stroke | Richard Lewar Centre of Excellence in Cardiovascular Research

ROYAL COLLEGE OF PHYSICIANS & SURGEONS OF CANADA ACCREDITED PROGRAM

Alice YY Cheng, MD, FRCPC

Associate Professor, Department of Medicine, University of Toronto
Endocrinologist, Trillium Health Partners in Mississauga and St. Michael's Hospital in Toronto

David Fitchett, MD, FRCPC

Associate Professor of Medicine, University of Toronto
Cardiologist, St Michael's Hospital

"Diabetes and Cardiovascular Disease: A Practical Guide for Specialists Managing Patients With or At Risk for Cardiovascular Disease"

LEARNING OBJECTIVES:

1. Outline the impact of T2DM upon CV morbidity and mortality
2. Describe the role that approved anti-hyperglycemic therapies play in reducing CV risk
3. Select appropriate anti-hyperglycemic agents in order to reduce CV risk in patients with T2DM
4. Develop an integrated management plan in order to meet patient needs and reduce T2DM morbidity and mortality

DATE/TIME:

Sunday, October 21, 2018
7:00 pm – Reception, Dinner and Lecture

VENUE:

Oliver & Bonacini Café Grill
33 Yonge Street, Toronto, ON M5E 1G4

REGISTRATION:

Event is free to attend but registration is required.
Please *click here to register* by October 19th. Space is limited so please register soon.

This is an accredited program. Participants will be able to claim up to 3.0 hours of the Royal College of Physicians & Surgeons of Canada – 3.0 Section 1 credits

University of Toronto's Heart & Stroke/Richard Lewar Centre of Excellence in Cardiovascular Research (HSRLCE) is pleased to present:

"Diabetes Connect 2019: A Practicum for Primary Care"

By the end of this session, participants will be able to:

1. Discuss the interplay between diabetes, cardiovascular and renal disease
2. Investigate and manage cardiovascular and renal issues in patients with diabetes
3. Apply evidence and guidelines recommendations to reduce cardiovascular and renal risk for patients with diabetes

ACCREDITATION: We are pleased to announce that this program has been certified by the College of Family Physicians of Canada and the Ontario Chapter for up to **5.0 Mainpro+** credits.

REGISTRATION: The event is free to attend but registration is required. Space is limited. Please register by *November 12th* on our website: https://hsrlce.utoronto.ca/events/event-registration/

Date: **Friday, November 15, 2019**

Time: **8:00 am – 2:10 pm**

Venue: **The Estates of Sunnybrook**
Vaughan Estate – Courtyard Ballroom
80 Armistice Drive
North York, ON M4N 1J8

AGENDA

8:00-8:45	Breakfast
8:45-9:00	**Welcome and Current State of Diabetes** - *Drs. Julie Lovshin & Alice Cheng* *Learning objectives:* • *Explain what is the magnitude of the diabetes epidemic* • *Highlight the gaps in care for our patients in 2019*
9:00-9:30	**Update on CVOTs in Diabetes** - *Dr. Megha Poddar* *Learning objectives:* • *Review 2018 Diabetes Canada Guidelines highlighting CV recommendations* • *Review recently published trials in CVOT in Diabetes*

9:30-10:00	**Why do Certain Antihyperglycemics Provide Benefit?** *-Dr. Julie Lovshin* *Learning objectives:* • *Discuss mechanisms of cardiovascular and renal disease in Type 2 Diabetes* • *Explain cardioprotective pathways whereby GLP-1 receptor agonists reduce CV events in Type 2 Diabetes* • *Explain cardioprotective pathways whereby SGLT-2 inhibitors reduce CV events in Type 2 Diabetes*
10:00-10:30	Panel Q&A
10:30-10:45	Nutrition Break
10:45-11:15	**Cardiology view of Diabetes Management** *-Dr. Mina Madan* *Learning objectives:* • *To understand the assessment of cardiovascular risk among patients with diabetes.* • *To learn about management strategies for CAD and CHF in patients with diabetes.*
11:15-11:45	**Nephrology view of Diabetes Management** *-Dr. Veronica Silva* *Learning objectives:* • *Define Chronic Kidney Disease in Diabetes and its prevalence.* • *Discuss current standards of care in the treatment of CKD with diabetes and treatment care gaps.* • *Apply evidence from recent clinical trials in patients with diabetes with renal outcomes.*
11:45-12:15	Panel Q&A
12:15-12:45	Lunch
12:45-1:15	**Keto Diet - Practical Approach** - *Wendy Graham, RD, CDE* *Learning objectives:* • *Recognize the difference between low carbohydrate and ketogenic diet* • *Recognize contraindications for using a ketogenic diet for a person with type 2 diabetes* • *Describe medications that may require alterations* • *Describe the nutrient supplementation required with the ketogenic diet*
1:15-1:45	**Outcome vs Glycemic-Based Approach - Are We Ready?** - *Dr. Alice Cheng* *Learning objectives:* • *Differentiate between an outcome-based vs glycemic-based approach to antihyperglycemic management* • *Utilize multifactorial approach to managing diabetes*
1:45-2:15	Panel Q&A
2:15-2:30	**Closing Remarks** - *Dr. Julie Lovshin* *Learning objectives:* • *To summarize the key learnings of each of the lectures* • *To highlight the actionable tasks that we can all do to improve our management for our patients with diabetes.*

DIABETES CONNECT 2019: A PRACTICUM FOR PRIMARY CARE – NOV. 15, 2019

SPEAKER BIOS

Alice Y.Y. Cheng, MD, FRCPC

Dr. Cheng is a member of the Division of Endocrinology and Metabolism at Credit Valley Hospital in Mississauga and St. Michael's Hospital in Toronto and is an Associate Professor in the Department of Medicine at the University of Toronto. She completed medical school, internal medicine and Endocrinology training at the University of Toronto and has completed the Master Teacher Program offered through the Department of Medicine. She has served on the Expert Committee for the 2003 Diabetes Canada clinical practice guidelines, the Steering and Expert Committees for the 2008 revision and served as Chair of the 2013 Diabetes Canada clinical practice guidelines. She is currently Secretary-Treasurer of the Canadian Society of Endocrinology and Metabolism and the Chair of the Guidelines Committee. She is actively involved in continuing medical education and has received a Certificate of Recognition from the Ontario College of Family Physicians, the national Charles H. Best Award and most recently, the Gerald S. Wong Service Award from Diabetes Canada in recognition of her contributions.

Wendy Graham, RD, CDE

Wendy is a Clinical Dietitian and Certified Diabetes Educator, and has over 30 years experience in the field of diabetes education. She received a Bachelor of Science in Human Nutrition at University of Guelph, did her internship at St. Michael's hospital, Toronto. She was involved in the original setup of the Diabetes Education program at Credit Valley Hospital.

Wendy is recognized for being energetic and dedicated in the delivery of diabetes education. She was nominated for Canadian Diabetes Educator of the Year in 2000. She was co-creator and partner of Food Quest, a computer program for diabetes food management released in 1997. She has been a member of the CDA national nutrition committee and DES Chapter treasure.

In her present role as mentor/best practice facilitator for Waterloo Wellington Diabetes, she supports health care providers to enhance their knowledge and skill in delivering diabetes care and management. She also develops tools and resources as well as contributing to the content of the regional website.

Julie A. Lovshin, MD, PhD, FRCPC

Dr. Lovshin is a Clinician Scientist and Assistant Professor of Medicine in the Division of Endocrinology and Metabolism, Department of Medicine, at the University of Toronto. Dr. Lovshin is an Endocrinologist who specializes in diabetes clinical care, with an emphasis on renal and cardiovascular complications. Dr. Lovshin directs the Diabetes Complications Clinical Research Laboratory at Sunnybrook Health Sciences Research Centre, Toronto, Canada, where her research is focused on mechanistic human investigation in renal, retinal and cardiovascular disease and function.

Dr. Lovshin completed a PhD with Dr. Daniel Drucker on incretin hormones including GLP-1 and GLP-2 at the University of Toronto. She then went on to complete her medical training and residency in Internal Medicine and Endocrinology and Metabolism also at the University of Toronto. After her medical training, she completed 5-year post-doctoral research studies in clinical investigation in Type 1 and Type 2 diabetes, training with Dr. Daniel Drucker and Dr. David Cherney on renal and systemic hemodynamic function (focusing on incretin-based diabetes therapies and SGLT-2i), as well as with Dr. Bruce Perkins co-leading the Canadian Study for Longevity in Type 1 Diabetes. Dr. Lovshin has also completed research methodology and epidemiology training at the Harvard School of Public Health, Boston, MA.

Mina Madan, MD, MHS, FRCPC, FSCAI

Dr. Madan is an academic interventional cardiologist and clinical trialist at the Schulich Heart Centre, Sunnybrook Health Sciences Centre. She is an Affiliate Scientist in the Evaluate Clinical Sciences Platform of the Sunnybrook Research Institute. She is an Associate Professor of Medicine at the University of Toronto. Her career has been focused on modernizing the practice of Interventional Cardiology through drugs and device research, knowledge translation of research findings by creating innovative teaching forums, and professional practice development. She has 20 years of experience with leadership positions in the design and conduct of clinical trials in interventional cardiology and cardiovascular medicine. She was appointed the Director of Interventional Cardiology clinical trials research at Sunnybrook in 2006. Her research interests include: 1) Studying the efficacy and safety of antiplatelet and anticoagulant therapies administered to patients undergoing percutaneous coronary interventions 2) The study of factors, techniques, and strategies that impact on the delivery of care in acute ST-elevation myocardial infarction and acute coronary syndromes and 3) secondary prevention strategies in cardiovascular medicine. 4) Diagnosis and management of patients with spontaneous coronary artery dissection (SCAD).

Megha Poddar, MD, FRCPC

Dr. Poddar completed her fellowship in Endocrinology and Metabolism from Western University following a residency in Internal Medicine at McMaster University. She has been a fellow of the Royal College of Physicians and Surgeons of Canada since 2014 and has additional training in Obesity and Bariatric Medicine from McMaster University. She is one of the few endocrinologist in Ontario who is certified by the American board of obesity medicine. Dr. Poddar recently joined LMC Diabetes Endocrinology Clinics, a large group of endocrinologists at their new Downtown Toronto location.

Veronica Silva, MD

Dr. Silva graduated from Evangelica Medical School in El Salvador. She completed Internal Medicine Residency training at Queen's University, and obtained Nephrology fellowship from the University of Western Ontario. She is certified as a Hypertension Specialist by the American Society of Hypertension (now known as American Heart Association).

Dr. Silva's clinical interests are in the area of Hypertension, Peritoneal Dialysis and Glomerulonephritis. Her positions include: Staff Nephrologist at Trillium Health Partners since 2012; Co-Chair of the Mississauga Hypertension Clinic, founded in 2014; and Co-Chair Peritoneal Dialysis Council, Trillium Health Partners (THP). She is one of the Clinician leads in the opening of the Glomerulonephritis Clinic at Trillium Health Partners, May 2019.

In terms of research and education, Dr. Silva obtained Investigator status, Institute for Better Health, 2018; and is a Clinical Lecturer for the University of Toronto, since 2013.

INVITATION WEBINAR SERIES

BE IT RESOLVED THAT...

An educational debate on optimal cardiorenal protection of patients with or without diabetes

DEBATE TOPICS - BE IT RESOLVED THAT...

1. Be it resolved that the first agent initiated in all patients with type 2 diabetes should be an SGLT2i/GLP1-RA in place of metformin.
2. Be it resolved that in patients with HF (with or without T2DM) an SGLT2i should be prioritized over an ARNi.
3. Be it resolved that a GLP1-RA should be prioritized over a SGLT2i for people with T2DM and ASCVD.
4. Be it resolved that in patients with albuminuria, and low-normal blood pressure (with or without T2DM), initiating an SGLT2i over an ACE/ARB will provide more nephroprotection.

PROGRAM LEARNING OBJECTIVES

Upon completion of this program, participants will be better able to:

- Discuss the cardiorenal protective role of sodium-glucose transport protein 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1-RA) in patients with and without diabetes.
- Compare different treatment sequencing options for SGLT2i and GLP1-RA in type 2 diabetes mellitus (T2DM), as well as in chronic kidney disease and heart failure populations with or without type 2 diabetes, based on recently published data.

For more details and to view speaker bios, please visit the Heart & Stroke/Richard Lewar Centre of Excellence in Cardiovascular Research website - https://hsrlce.utoronto.ca

ACCREDITATION

This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, approved by Continuing Professional Development, Temerty Faculty of Medicine, University of Toronto, for a maximum of 1.5 credits.

This program was co-developed and planned with the University of Toronto to achieve scientific integrity, objectivity and balance, with an unrestricted grant from the Boehringer Ingelheim and Eli Lilly Canada Alliance in Diabetes.

TEMERTY FACULTY OF MEDICINE
UNIVERSITY OF TORONTO
Continuing Professional Development

REGISTER FOR ONE OR MORE DATES

MARCH 29, 2021
8:00 - 9:30 PM Eastern Time

Moderator
Thao Huynh, MD, PhD

Debaters

Jay Udell, MD, MPH, FRCPC	Steve Wong, MD, FRCPC
Cardiologist	Internist
Toronto, ON	Vancouver, BC

Topics Topics 2 and 3 (see details on the left)

REGISTER NOW!

APRIL 8, 2021
8:00 - 9:30 PM Eastern Time

Moderator
Sara Stafford, MD

Debaters

Alice Y. Y. Cheng, MD, FRCPC	Steve Wong, MD, FRCPC
Endocrinologist	Internist
Toronto, ON	Vancouver, BC

Topics Topics 1 and 3 (see details on the left)

REGISTER NOW!

APRIL 28, 2021
8:00 - 9:30 PM Eastern Time

Moderator
Sara Stafford, MD

Debaters

Alice Y. Y. Cheng, MD, FRCPC	Louis Girard, MD, MBT, FRCPC
Endocrinologist	Nephrologist
Toronto, ON	Calgary, AB

Topics Topics 1 and 4 (see details on the left)

REGISTER NOW!

Upon registration, you should receive a confirmation email from diabeteslearningonline.com. Please check your spam folder if you do not receive the email within a few minutes.

THE HEART, THE KIDNEY, AND SGLT2 INHIBITION: FROM CLINICAL TRIALS TO PATIENT CARE

FRIDAY, FEBRUARY 26, 2021

12:00PM – 1:00PM EST

Learning Objectives:

1. Describe the effects of SGLT2 inhibitors on HF-related outcomes – cardiologist perspective
2. Interpret the evidence for SGLT2 inhibitors from clinical trials in patients with CKD with and without diabetes – nephrologist perspective
3. Discuss practical considerations regarding the use of SGLT2 inhibitors – endocrinologist perspective

Speakers:

David Cherney
MD CM, PhD, FRCP(C)

Professor of Medicine - University of Toronto
Clinician Scientist - Division of Nephrology, University Health Network
Senior Scientist, Toronto General Hospital Research Institute
Director, Renal Physiology Laboratory, UHN

Alice Y. Y. Cheng
MD, FRCPC

Associate Professor, Department of Medicine, University of Toronto
Endocrinologist, Trillium Health Partners in Mississauga and St. Michael's Hospital

Jacob Udell
MD, MPH, FRCPC

Associate Professor, Division of Cardiology, Department of Medicine & Institute of Health Policy, Management and Evaluation, University of Toronto
Cardiologist, Women's College Hospital
Scientist, Women's College Research Institute

Moderator:

Michael E. Farkouh
MD, MSc, FRCPC, FACC, FAHA

Peter Munk Chair in Multinational Clinical Trials
Director, Heart & Stroke/Richard Lewar Centre of Excellence in Cardiovascular Research, University of Toronto
Vice-Chair, Research & Professor of Medicine, Department of Medicine, University of Toronto

TO REGISTER:

To register for this program please CLICK HERE
or go to: www.joinwebinar.com, enter webinar ID: 979-305-691
and enter your email address

Heart & Stroke Richard Lewar Centre of Excellence in Cardiovascular Research

TEMERTY FACULTY OF MEDICINE UNIVERSITY OF TORONTO

AstraZeneca

THE HEART, THE KIDNEY, AND SGLT2 INHIBITION: FROM CLINICAL TRIALS TO PATIENT CARE

FACULTY BIOS

Alice Y.Y. Cheng, MD, FRCPC

Dr. Cheng is a member of the Division of Endocrinology and Metabolism at Trillium Health Partners in Mississauga and St. Michael's Hospital in Toronto and is an Associate Professor in the Department of Medicine at the University of Toronto. She completed medical school, internal medicine and Endocrinology training at the University of Toronto and has completed the Master Teacher Program offered through the Department of Medicine. She has served on the Expert Committee for the 2003 Diabetes Canada clinical practice guidelines, the Steering and Expert Committees for the 2008 revision and served as Chair of the 2013 Diabetes Canada clinical practice guidelines. She is currently the Chair of the Professional Section of Diabetes Canada and an Associate Editor for the Canadian Journal of Diabetes. She has received a Certificate of Recognition from the Ontario College of Family Physicians, the national Charles H. Best Award and the Gerald S. Wong Service Award from Diabetes Canada in recognition of her contributions.

David Cherney, MD, PhD

Following his clinical training in Nephrology, Dr. Cherney completed his PhD in human renal physiology at the Institute of Medical Science, University of Toronto in 2008. He is currently Professor in the Department of Medicine, University of Toronto and a Clinician Scientist at the University Health Network and Mount Sinai Hospitals, where he is director of the Renal Physiology Laboratory. He is supported by the Canadian Institutes of Health Research, the JDRF, the Heart and Stroke Richard Lewar Centre of Excellence, the Heart and Stroke Foundation of Canada and the Banting and Best Diabetes Centre. He is also supported by a Department of Medicine, University of Toronto Merit Award. Dr. Cherney's research program focuses on physiological factors that initiate renal disease in patients with diabetes, such as renal hyperfiltration and inflammation, and the role of the cardiorenal axis in diabetes. His research group is also involved in early and late phase clinical trials in the cardiorenal-metabolic field, including several primary renal outcome trials in patients with and without diabetes. Dr. Cherney's research program is closely aligned with his integrated and multidisciplinary cardiac-renal-endocrine clinic at the University Health Network, which maintains a strong emphasis on the prevention of diabetic nephropathy and cardiovascular disease. In 2019, he received the American Society of Nephrology (ASN) Distinguished Researcher Award for outstanding contributions to nephrology. In 2019 he also received the Diabetes Canada/CIHR - Institute of Nutrition Diabetes and Metabolism (INMD) Young Scientist Award.

Michael Farkouh, MD, MSc, FRCPC, FACC, FAHA

Dr. Farkouh is the Peter Munk Chair in Multinational Clinical Trials at the Peter Munk Cardiac Centre, Director of the Heart and Stroke/Richard Lewar Centre of Excellence in Cardiovascular Research, Professor and Vice-Chair, Research, Department of Medicine at the University of Toronto. He is internationally known for his work on the management of acute coronary syndromes and has a special interest and expertise in the field of cardiovascular disease in patients with diabetes. He graduated from the Schulich School of Medicine at Western University & completed his internal medicine and cardiology training at the Mayo Clinic and the Icahn School of Medicine at Mount Sinai New York respectively. He holds an MSc in clinical epidemiology from McMaster University. He served as the founding director of the Mount Sinai Cardiovascular Clinical Trials Unit in New York City. Dr. Farkouh has received the Gold Medal from John Paul II Hospital in Krakow, was elected Teacher of the Year at the Mayo Clinic & was awarded the Jan J. Kellermann Memorial Award for Cardiovascular Disease Prevention from the International Academy of Cardiology. Dr. Farkouh serves as section editor for Diabetes at the Journal of the American College of Cardiology.

Jacob Udell, MD, MPH, FRCPC

Dr. Udell is a Cardiologist and Clinician-Scientist at Women's College Hospital and the Peter Munk Cardiac Centre at the University Health Network and an Associate Professor of Medicine at the University of Toronto. He and his group's focus is in the conduct of large observational studies and clinical trials testing strategies and treatments for primary and secondary prevention of ischemic heart disease and heart failure. As a co-PI, national lead investigator, or steering committee member, he has recently published the INVESTED randomized controlled trial, which investigated the cardiovascular benefit of a high-dose versus usual-dose influenza vaccine; as well as the SCORED trial, studying sotagliflozin in patients with type 2 diabetes and chronic kidney disease. Currently he is the co-PI of a CIHR SPOR Innovative Clinical Trial Grant testing a provincial report card strategy on primary care performance measures for cholesterol management and also a co-lead of the international, multicentre EMPACT-MI trial, testing the early use of an SGLT2 inhibitor in high-risk heart attack patients to prevent the onset of heart failure.

Invitation

Straight from the Heart

Insights on optimal cardio-protection

Program Overview

SGLT2is and GLP1-RAs have proven to be effective in reducing cardiovascular risk and improving cardiometabolic health in several patient populations that are seen by cardiologists including ASCVD and HF with or without diabetes. This case-based program offers practical tips and tricks that can be used in daily practice and will help increase confidence with the initiation and use of the cardioprotective therapies.

Learning Objectives

At the end of this program, participants will be better able to:

- Recognize the importance of early initiation of cardioprotective therapies (SGLT2 inhibitors) in patients **with heart failure with reduced ejection fraction (with or without diabetes)**;
- Recognize the importance of early initiation of cardioprotective therapies (SGLT2 inhibitors and GLP-1 receptor agonists) in patients with **atherosclerotic cardiovascular disease and diabetes**;
- Initiate SGLT2 inhibitors and GLP-1 receptor agonists in **appropriate patients** using guideline-recommended strategies;
- Advise patients on the **safe use** of SGLT2 inhibitors and GLP-1 receptor agonists

Registration

Monday, November 29, 2021

7:00pm - 8:30pm

Online via Zoom

Upon registration, you should receive a confirmation email from **info@straightfromthehearthf.com**

Please check your spam folder if you do not receive the email within a few minutes.

Moderator

Ajay Kapur, MD

FRCPC Deputy Chief Medical Information Office, St. Joseph's Health Centre

Speaker

Kim Connelly, MD

MBBS, FRACP, PhD Associate Professor of Medicine, University of Toronto, Cardiologist, St. Michael's Hospital, Toronto, ON

REGISTER NOW!

https://www.straightfromthehearthf.com/?mID=359

Accreditation

This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, approved by Continuing Professional Development, Temerty Faculty of Medicine, University of Toronto, for a maximum of 1.5 credits.

This program was co-developed and planned with the University of Toronto's Heart & Stroke/Richard Lewar Centre of Excellence in Cardiovascular Research to achieve scientific integrity, objectivity and balance, with an unrestricted grant from the Boehringer Ingelheim and Eli Lilly Canada Alliance in Diabetes.

Heart & Stroke Richard Lewar Centre of Excellence in Cardiovascular Research

TEMERTY FACULTY OF MEDICINE
UNIVERSITY OF TORONTO
Continuing Professional Development